JP7616794B2 - エストロゲン受容体アンタゴニストのレジメン - Google Patents

エストロゲン受容体アンタゴニストのレジメン Download PDF

Info

Publication number
JP7616794B2
JP7616794B2 JP2022500672A JP2022500672A JP7616794B2 JP 7616794 B2 JP7616794 B2 JP 7616794B2 JP 2022500672 A JP2022500672 A JP 2022500672A JP 2022500672 A JP2022500672 A JP 2022500672A JP 7616794 B2 JP7616794 B2 JP 7616794B2
Authority
JP
Japan
Prior art keywords
composition
compound
inhibitor
administered
estrogen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540421A5 (https=
JP2022540421A (ja
Inventor
サイラス エル． ハーモン，
ピーター ジェイ． クシュナー，
デイビッド シー． マイルス，
レスリー ホッジズ ギャラガー，
リチャード サン，
Original Assignee
オレマ ファーマシューティカルズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレマ ファーマシューティカルズ インク． filed Critical オレマ ファーマシューティカルズ インク．
Publication of JP2022540421A publication Critical patent/JP2022540421A/ja
Publication of JP2022540421A5 publication Critical patent/JP2022540421A5/ja
Priority to JP2024167449A priority Critical patent/JP2025000782A/ja
Application granted granted Critical
Publication of JP7616794B2 publication Critical patent/JP7616794B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022500672A 2019-07-07 2020-07-06 エストロゲン受容体アンタゴニストのレジメン Active JP7616794B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024167449A JP2025000782A (ja) 2019-07-07 2024-09-26 エストロゲン受容体アンタゴニストのレジメン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962871191P 2019-07-07 2019-07-07
US62/871,191 2019-07-07
US201962871592P 2019-07-08 2019-07-08
US62/871,592 2019-07-08
PCT/US2020/040863 WO2021007146A1 (en) 2019-07-07 2020-07-06 Regimens of estrogen receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024167449A Division JP2025000782A (ja) 2019-07-07 2024-09-26 エストロゲン受容体アンタゴニストのレジメン

Publications (3)

Publication Number Publication Date
JP2022540421A JP2022540421A (ja) 2022-09-15
JP2022540421A5 JP2022540421A5 (https=) 2023-07-11
JP7616794B2 true JP7616794B2 (ja) 2025-01-17

Family

ID=74115136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500672A Active JP7616794B2 (ja) 2019-07-07 2020-07-06 エストロゲン受容体アンタゴニストのレジメン
JP2024167449A Pending JP2025000782A (ja) 2019-07-07 2024-09-26 エストロゲン受容体アンタゴニストのレジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024167449A Pending JP2025000782A (ja) 2019-07-07 2024-09-26 エストロゲン受容体アンタゴニストのレジメン

Country Status (9)

Country Link
US (1) US12370181B2 (https=)
EP (1) EP3993785A4 (https=)
JP (2) JP7616794B2 (https=)
KR (1) KR20220034129A (https=)
CN (1) CN114302722A (https=)
AU (1) AU2020311337B2 (https=)
CA (1) CA3144791A1 (https=)
MX (2) MX2022000279A (https=)
WO (1) WO2021007146A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
EP4304574A4 (en) * 2021-03-11 2024-11-20 Atossa Therapeutics, Inc. ENDOXIFEN FOR THE TREATMENT OF OVARIAN CANCER
WO2023283329A1 (en) * 2021-07-08 2023-01-12 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023059714A1 (en) * 2021-10-06 2023-04-13 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
CN114933558B (zh) * 2022-07-26 2022-11-22 常熟药明康德新药开发有限公司 手性硝基化合物催化还原制备手性氨基化合物的方法
CA3262155A1 (en) 2022-08-11 2024-02-15 Evexta Bio COMPOUNDS FOR CANCER TREATMENT
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538725A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
WO2018064231A1 (en) 2016-09-27 2018-04-05 Radius Health, Inc. Methods for treating ovarian cancer
JP2018530549A (ja) 2015-10-01 2018-10-18 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
WO2018197653A1 (en) 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69531476T2 (de) 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergische Modulatoren
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AU2001271785A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of statins, estrogenic agents and optionally estrogens
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
WO2002003986A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
MXPA03000170A (es) 2000-07-06 2003-05-27 Wyeth Corp Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos.
AU7178301A (en) 2000-07-06 2002-01-21 American Home Prod Methods for increasing nitric oxide synthase activity
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
PL374215A1 (en) 2001-08-11 2005-10-03 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2006206446A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015136016A2 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109843882A (zh) 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
EP3640251B1 (en) 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CR20200621A (es) 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
CN112424205B (zh) 2018-07-12 2023-10-31 伊莱利利公司 选择性的雌激素受体降解剂
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
TW202011966A (zh) 2018-07-23 2020-04-01 瑞士商赫孚孟拉羅股份公司 用pi3k抑制劑gdc-0077治療癌症之方法
JP7571006B2 (ja) 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
CA3169679A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538725A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
JP2018530549A (ja) 2015-10-01 2018-10-18 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
WO2018064231A1 (en) 2016-09-27 2018-04-05 Radius Health, Inc. Methods for treating ovarian cancer
WO2018197653A1 (en) 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Also Published As

Publication number Publication date
AU2020311337A1 (en) 2022-01-20
AU2020311337B2 (en) 2026-02-26
JP2025000782A (ja) 2025-01-07
CN114302722A (zh) 2022-04-08
WO2021007146A1 (en) 2021-01-14
EP3993785A4 (en) 2023-08-02
MX2022000279A (es) 2022-02-03
US12370181B2 (en) 2025-07-29
CA3144791A1 (en) 2021-01-14
US20220265616A1 (en) 2022-08-25
US20230109666A2 (en) 2023-04-06
KR20220034129A (ko) 2022-03-17
JP2022540421A (ja) 2022-09-15
EP3993785A1 (en) 2022-05-11
MX2025003482A (es) 2025-05-02

Similar Documents

Publication Publication Date Title
JP7616794B2 (ja) エストロゲン受容体アンタゴニストのレジメン
JP7708772B2 (ja) エストロゲン受容体関連疾患の治療方法
JP2013502424A (ja) 熱ショックタンパク質結合化合物、組成物、およびそれらを製造するための方法
EP3180004B1 (en) Cancer therapeutics
US20250049768A1 (en) Methods of treating estrogen receptor-associated diseases
WO2020253762A1 (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
US11427543B2 (en) Compounds for targeting cancer stem cells
TW202525792A (zh) 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物
Liao et al. Discovery of Thiadiazoleamide Derivatives as Potent, Selective, and Orally Available Antagonists Disrupting Androgen Receptor Homodimer
CN104884061A (zh) 用于治疗Rac-GTP酶介导的病症的化合物
TWI857798B (zh) 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物
HK40081119B (en) Compositions for use in a method of treating an estrogen receptor associated cancer
HK40081119A (en) Compositions for use in a method of treating an estrogen receptor associated cancer
Catalfano et al. Optimization of triazole-based small molecule disruptors of the Aha1/Hsp90 complex that manifest potent activities
WO2018175965A1 (en) Antiestrogens for cancer therapy
Zhu et al. Synthesis and biological evaluation of 2-(2-methyl-6-(quinolin-3-yl) nicotinoyl)-N-alkylhydrazine-1-carboxamide derivtives as anti-tumor agents targeting Nur77
Ambedkar et al. Identification of a Novel 1, 2 Oxazine That Can Induce Apoptosis by Targeting NF-κB in Hepatocellular Carcinoma Cells
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
JP2025521593A (ja) ３βＨＳＤ１阻害剤及び組成物ならびにそれらの使用
CN119241528A (zh) 苯并[b]氧杂环庚烷类化合物及其应用
Harcken et al. Identification and Optimization of a Series of Non-Steroidal Trifluoromethylcarbinol Glucocorticoid Receptor Agonists
Lemos Design and synthesis of aminoxanthone derivatives as promising disruptors of p53: MDM2 interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241230

R150 Certificate of patent or registration of utility model

Ref document number: 7616794

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150